Ribociclib

Contraindicated

Ribociclib Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of fatal toxicity Details Ribociclib Simvastatin Flolipid Explained Increased simvastatin exposure and an increased the risk of myopathy and rhabdomyolysis Details Ribociclib Dihydroergotamine Injection DHE-45® Injection Increased dihydroergotamine exposure and an increased risk of dihydroergotamine-related adverse effects Details Ribociclib Dihydroergotamine Nasal Spray Migranal Increased dihydroergotamine exposure and an increased risk of dihydroergotamine-related adverse effects Details Ribociclib Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Ribociclib Ivabradine Corlanor Increased ivabradine exposure, an increased risk of ivabradine-related adverse effects and an increased risk of QT prolongation Details Ribociclib Ketoconazole Topical Extina® Foam Increased ribociclib exposure, an increased risk of ribociclib-related adverse reaction, an increased ketoconazole exposure, an in... Details Ribociclib Lefamulin Xenleta Increased lefamulin exposure, an increased risk of lefamulin-related adverse reactions, an increased sensitive CYP3A4 substrate ex... Details Ribociclib Lovastatin Altocor® Increased lovastatin exposure and an increased risk of myopathy or rhabdomyolysis Details Ribociclib Lurasidone Latuda Increased lurasidone exposure Details Ribociclib Naloxegol Movantik Increased naloxegol exposure and an increased risk of naloxegol-related adverse effects Details

Major

Ribociclib Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine and morphine exposure Details Ribociclib Abametapir Explained Increased exposure of CYP3A4 substrate Details Ribociclib Clindamycin ANTIROBE Explained Increased exposure of CYP3A4 substrate and an increased risk of CYP3A4 substrate-related adverse reactions Details Ribociclib Amitriptyline Elavil Explained An increased risk of QT interval prolongation Details Ribociclib Sertraline Explained An increased risk of QT interval prolongation Details Ribociclib Buprenorphine Belbuca Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Ribociclib Relugolix Orgovyx Explained Increased risk of QT interval prolongation Details Ribociclib Abemaciclib Verzenio Explained Increased exposure of CYP3A4 substrate and an increased risk of CYP3A4 substrate-related adverse reactions Details Ribociclib Acalabrutinib Calquence Increased exposure of CYP3A4 substrate and an increased risk of CYP3A4 substrate-related adverse reactions Details Ribociclib Ado-Trastuzumab Emtansine Injection KADCYLA Increased exposure of cytotoxic component DM1 (maytansine derivative) and risk of toxicity Details Ribociclib Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Ribociclib Apixaban Eliquis Explained Increased apixaban exposure Details Ribociclib Arsenic Trioxide Trisenox An increased risk of QT interval prolongation Details Ribociclib Aripiprazole Injection Abilify Increased ARIPiprazole exposure and an increased risk of QT interval prolongation Details Ribociclib Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation Details Ribociclib Asciminib Scemblix Increased asciminib exposure, increased CYP3A4 substrate exposure, increased risk of asciminib-related adverse effects and an incr... Details Ribociclib Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation Details Ribociclib Atogepant Qulipta Increased atogepant exposure Details Ribociclib Avapritinib Ayvakit Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Ribociclib Azithromycin AzaSite An increased risk of QT interval prolongation Details Ribociclib Cariprazine Vraylar Explained Increased exposure to cariprazine and its active metabolite, didesmethylcariprazine Details Ribociclib Alfuzosin UroXatral An increased risk of QT interval prolongation Details Ribociclib Amlodipine Amvaz® Increased amLODIPine exposure and an increased risk of hypotension and edema Details Ribociclib Anagrelide Agrylin An increased risk of QT interval prolongation Details Ribociclib Axitinib Inlyta Increased exposure of CYP3A4 substrate and an increased risk of CYP3A4 substrate-related adverse reactions Details Ribociclib Beclomethasone Nasal Spray Beconase Increased beclomethasone exposure and an increased risk of beclomethasone-related adverse reactions Details Ribociclib Beclomethasone Oral Inhalation Beclovent® Increased beclomethasone exposure and an increased risk of beclomethasone-related adverse reactions Details Ribociclib Bedaquiline Sirturo Increased bedaquiline exposure and an increased risk of QT interval prolongation Details Ribociclib Bosutinib Bosulif Increased bosutinib exposure Details